Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction PTX+Bevacizumab followed by Atezolizumab+Nab-PTX in mTNBC
NCT06793553Phase 2Recruiting
- Sponsor
- Japan Breast Cancer Research Group
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and bevacizumab in triple-negative breast cancer (TNBC), sponsored by Japan Breast Cancer Research Group. Primary endpoint: Progression-free survival at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
paclitaxelbevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06793553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793553.